|
TOP NEWS
POLICY & REGULATION
ENFORCEMENT & COMPLIANCE
LITIGATION
EXPERT ANALYSIS
FDA Moves Leave Peptides In A Legal Gray Zone
While the U.S. Food and Drug Administration has taken a concrete step forward on reclassifying certain peptides, the practical consequence of their interim status cannot be overstated — these substances are no longer designated as posing a significant safety risk, but they have not been affirmatively authorized for compounding, say attorneys at Sheppard.
Read full article »
| Save to favorites »
LEGAL INDUSTRY
|